Horizon Pharma

Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Horizon's Q1 2021 results were good considering Tepezza's supply disruption. Tepezza sales resumed in early Q1 and it is off to a strong start with record patient enrollment forms in April.

Horizon Therapeutics: Tepezza Relaunch Off To A Strong Start

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced data presentations at the EULAR European Congress of Rheumatology, June 2 – 5, 2021. At this year's meeting, Horizon will present data on HZN-4920 (VIB4920), the company's investigational compound under evaluation for rheumatoid arthritis in an oral session. Additional presentations will include an update on the PROTECT trial evaluating the use of KRYSTEXXA (pegloticase injection) in people with chronic gout refrac

Horizon Therapeutics plc Highlights Expanding R&D Efforts with Data Presentations at the EULAR European Congress of Rheumatology

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to the Great Place to Work® Best Workplaces in Chicago 2021 list, ranking No. 13 in the large company category. The list includes 39 other top large sized companies, as well as 50 best small-to-medium workplaces in the Chicago area. “We are proud to be named on the Best Workplaces in Chicago 2021 list for the fifth consecutive year,” said Tim Walbert, chairman, president and chief executive o

Horizon Therapeutics plc Named One of the 2021 Best Workplaces in Chicago™ by Great Place to Work®

Cerecor

CRISPR Therapeutics

Johnson & Johnson

Eli Lilly

Schrodinger 

Takeda Pharmaceutical

Here are seven biotech stocks with loads of innovation and plenty of catalysts to make money for smart investors. The post 7 Best Biotech Stocks To Buy in 2021 as Innovation Takes Center Stage appeared first on InvestorPlace.

7 Best Biotech Stocks To Buy in 2021 as Innovation Takes Center Stage

DUBLIN--(BUSINESS WIRE)--Horizon ranked #1 in overall corporate reputation among U.S. patient groups that reported working with the company.

Horizon Therapeutics plc Ranked #1 in Overall Corporate Reputation Among U.S. Patient Groups that Report Working with the Company

Allakos Inc

ImmunityBio

I-Mab

Mind Medicine MindMed

SAGE Therapeutics

SpringWorks Therapeutics Inc

As the market gets back to normal, it's a great time to explore the pharma stocks that got lost in the vaccine frenzy of the past year. The post 7 of the Best Pharma Stocks to Buy Now appeared first on InvestorPlace.

7 of the Best Pharma Stocks to Buy Now

Freeport-McMoRan

Tilray Brands

Zillow

As investors were so righteously reminded on Friday, many of the day-to-day Wall Street prognostications and strategy calls are almost always “best guesses” or data-based “assumptions.

Why 4 Jefferies Top Growth Stocks to Buy May Be Perfect Ideas Now

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conference in May: Bank of America Securities 2021 Health Care Conference (Virtual) Date: Tuesday, May 11, 2021 Presentation Time: 3:30 p.m. ET The conference presentation will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizontherapeutics.com. A replay of the webcast will be available following the event. About Horizon Horizon i

Horizon Therapeutics plc to Present at the Bank of America Securities 2021 Health Care Conference

DUBLIN--(BUSINESS WIRE)--New analysis of UPLIZNA® (inebilizumab-cdon) for neuromyelitis optica spectrum disorder (NMOSD) has been published.

New Analysis of UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in Neurology Neuroimmunology & Neuroinflammation

Horizon (HZNP) misses estimates for earnings in the first quarter of 2021 while revenues beat the same.

Horizon's (HZNP) Q1 Earnings Miss Estimates, Revenues Beat

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Elizabeth H.Z. Thompson, Ph.D., executive vice president, research and development, has been named a 2021 Healthcare Businesswomen's Association (HBA) Luminary. Dr. Thompson will be honored at the 2021 HBA Woman of the Year virtual event today. The HBA is the leading nonprofit global organization committed to furthering the advancement and impact of women in health care. Dr. Thompson is being recognized as a r

Horizon Therapeutics plc Announces Elizabeth H.Z. Thompson as a Healthcare Businesswomen's Association 2021 Luminary

Horizon Therapeutics' (HZNP) CEO Tim Walbert on Q1 2021 Results - Earnings Call Transcript

Horizon Therapeutics reported a mixed quarter Wednesday, but raised its sales target for 2021. Still, HZNP stock dipped after the open.

Horizon Stock Dives As Guidance Boost Fails To Overcome Sales Miss

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of -57.14% and 4.88%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Horizon Therapeutics (HZNP) Misses Q1 Earnings Estimates

Shares of Horizon Therapeutics (NASDAQ:HZNP) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share were down 92.50% year over year to $0.03, which missed the estimate of $0.04.

Recap: Horizon Therapeutics Q1 Earnings

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc Reports First-Quarter 2021 Financial Results; Updating Full-Year 2021 Guidance to Incorporate Recently Acquired Viela Bio

Horizon Therapeutics plc Reports First-Quarter 2021 Financial Results; Updating Full-Year 2021 Net Sales Guidance and Full-Year Adjusted EBITDA Guidance to Incorporate Recently Acquired Viela Bio, Inc.

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc ranked #4 in overall corporate reputation among pharmaceutical and biotech companies.

Horizon Therapeutics plc Ranks Among the Top Companies in Overall Corporate Reputation in 2020 PatientView Survey of Patient Organizations Worldwide

CHARLOTTESVILLE, Va., April 21, 2021 /PRNewswire/ -- HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has identified a second drug target for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP) that was established in January 2019.

HemoShear Therapeutics Advances Second Novel Drug Target into Horizon Therapeutics plc Early Discovery Pipeline for Gout

Horizon Pharma is near a possible buy area ahead of its earnings report expected around May 5 . The post Earnings Season Preview: Horizon Pharma Near Buy Zone With EPS Due appeared first on Investor's Business Daily.

Earnings Season Preview: Horizon Pharma Near Buy Zone With EPS Due

NAARDEN, The Netherlands & MUNICH--(BUSINESS WIRE)--Forbion, a leading European life sciences venture capital firm, today announces the final close of its Forbion Growth Opportunities Fund I (“Forbion Growth I") at the hard cap amount of EUR 360 million (USD 428 million). Forbion Growth I is focused on investing in late-stage European life sciences companies. Pantheon, Eli Lilly and Company, Horizon Therapeutics plc (Nasdaq: HZNP), the Belgian Growth Fund, New Waves Investments, Wealth Manageme

Forbion Announces Final Close of Forbion Growth Opportunities Fund I at EUR 360 Million (USD 428 Million)

Horizon Therapeutics's shares are up almost 200% over the past 12 months, buoyed by mind-boggling sales of its new blockbuster drug.

3 Reasons to Buy Horizon Therapeutics Stock and 1 Not To

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics today announced new UPLIZNA® (inebilizumab-cdon) data being presented at the American Academy of Neurology 2021 Annual Meeting.

New Long-Term Data for UPLIZNA® (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD)

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced pooled data from the TEPEZZA® (teprotumumab-trbw) clinical trials are published in The Lancet Diabetes & Endocrinology.

New Integrated Data and Follow-up Outcomes From Two TEPEZZA® (teprotumumab-trbw) Pivotal Trials Published in The Lancet Diabetes & Endocrinology

Biotech stock Horizon Therapeutics is set up below a buy point, ahead of earnings, after soaring 102% in 2020. Can it do it again?

Biotech Stock On Earnings Win Streak Sets Up Bullish Chart

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its first-quarter 2021 financial results will be released on Wednesday, May 5, 2021. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results. The live webcast and a replay may be accessed at http://ir.horizontherapeutics.com. Please connect to the Company's website at least 15 minutes prior to the live webcast to e

News for Horizon Pharma Stock (HZNP)